Completed PHASE3 INTERVENTIONAL 1-arm NCT00751400

Naproxen Sodium Extended-Release Actual Use Study

An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting

Sponsor: Bayer

Conditions Pain

Interventions Naproxen Sodium ER (BAYH6689)

Updated 8 times since 2017 Last updated: Aug 12, 2015 Started: Jul 31, 2008 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00751400, this PHASE3 trial focuses on Pain and remains completed. Sponsored by Bayer, it has been updated 8 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Pegus Research, Inc.

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anoka, United States , Belton, United States , Blaine, United States , Bountiful, United States , Cary, United States , Chapel Hill, United States , Elk River, United States , Kenmore, United States , Oceanside, United States and 13 more locations